Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 622

1.

Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.

Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, Zoungas S, Perkovic V, Woodward M; ADVANCE Collaborative Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872. doi: 10.2215/CJN.13391118. Epub 2019 Jun 3.

PMID:
31160317
2.

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.

Warren AM, Knudsen ST, Cooper ME.

Expert Opin Ther Targets. 2019 Jul;23(7):579-591. doi: 10.1080/14728222.2019.1624721. Epub 2019 Jun 3.

PMID:
31154867
3.

Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.

Selvin E, Wang D, McEvoy JW, Juraschek SP, Lazo M, Hamet P, Cooper ME, Marre M, Williams B, Harrap S, Chalmers J, Woodward M.

Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13755. [Epub ahead of print]

PMID:
31050156
4.

The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.

Mohan V, Cooper ME, Matthews DR, Khunti K.

Diabetes Ther. 2019 Mar;10(Suppl 1):1-13. doi: 10.1007/s13300-019-0573-y. Epub 2019 Feb 13. Review.

5.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
6.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
7.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
8.

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.

Ohkuma T, Jun M, Rodgers A, Cooper ME, Glasziou P, Hamet P, Harrap S, Mancia G, Marre M, Neal B, Perkovic V, Poulter N, Williams B, Zoungas S, Chalmers J, Woodward M; ADVANCE Collaborative Group.

Hypertension. 2019 Jan;73(1):84-91. doi: 10.1161/HYPERTENSIONAHA.118.12060.

9.

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M.

J Hypertens. 2019 Jun;37(6):1294-1300. doi: 10.1097/HJH.0000000000002032.

PMID:
30540657
10.

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.

Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, Huet O, Seeber RM, Abhayawardana R, Johnstone EK, Golledge J, Wang Y, Jandeleit-Dahm KA, Cooper ME, Pfleger KD, Thomas MC.

J Clin Invest. 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10.

11.

Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy.

Chai Z, Wu T, Dai A, Huynh P, Koentgen F, Krippner G, Ren S, Cooper ME.

Diabetes. 2019 Feb;68(2):395-408. doi: 10.2337/db18-0712. Epub 2018 Nov 13.

PMID:
30425061
12.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
13.

Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis.

Brennan EP, Mohan M, McClelland A, de Gaetano M, Tikellis C, Marai M, Crean D, Dai A, Beuscart O, Derouiche S, Gray SP, Pickering R, Tan SM, Godson-Treacy M, Sheehan S, Dowdall JF, Barry M, Belton O, Ali-Shah ST, Guiry PJ, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2018 Dec;67(12):2657-2667. doi: 10.2337/db17-1317. Epub 2018 Sep 13.

14.

Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial.

Thomas MC, Woodward M, Li Q, Pickering R, Tikellis C, Poulter N, Cooper ME, Marre M, Zoungas S, Chalmers J; ADVANCE Collaborative Group.

J Am Heart Assoc. 2018 Jun 30;7(13). pii: e008226. doi: 10.1161/JAHA.117.008226.

15.

Cardiovascular Disease and Diabetic Kidney Disease.

Maqbool M, Cooper ME, Jandeleit-Dahm KAM.

Semin Nephrol. 2018 May;38(3):217-232. doi: 10.1016/j.semnephrol.2018.02.003. Review.

PMID:
29753399
16.

Pathophysiological Links Between Diabetes and Blood Pressure.

Libianto R, Batu D, MacIsaac RJ, Cooper ME, Ekinci EI.

Can J Cardiol. 2018 May;34(5):585-594. doi: 10.1016/j.cjca.2018.01.010. Epub 2018 Jan 31. Review.

PMID:
29731021
17.

Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture.

Cooper ME, El-Osta A, Allen TJ, Watson AMD, Thomas MC, Jandeleit-Dahm KAM.

Diabetes. 2018 May;67(5):785-790. doi: 10.2337/dbi18-0010. Review.

18.

New Glucose-Lowering Agents for Diabetic Kidney Disease.

de Vos LC, Hettige TS, Cooper ME.

Adv Chronic Kidney Dis. 2018 Mar;25(2):149-157. doi: 10.1053/j.ackd.2018.01.002. Review.

PMID:
29580579
19.

Ultrasound Combined with Microbubbles Enhances the Effects of Methylprednisolone in Lipopolysaccharide-Induced Human Mesangial Cells.

Sun PF, Tian T, Chen LN, Fu RG, Xu SS, Ai H, Wang B, Zhang J, Si RY, Chai Z, Cooper ME, Ren ST.

J Pharmacol Exp Ther. 2018 Jun;365(3):476-484. doi: 10.1124/jpet.117.246223. Epub 2018 Mar 16.

PMID:
29549156
20.

Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets.

Ju L, McFadyen JD, Al-Daher S, Alwis I, Chen Y, Tønnesen LL, Maiocchi S, Coulter B, Calkin AC, Felner EI, Cohen N, Yuan Y, Schoenwaelder SM, Cooper ME, Zhu C, Jackson SP.

Nat Commun. 2018 Mar 14;9(1):1087. doi: 10.1038/s41467-018-03430-6.

21.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

22.

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, Gray SP, Pickering R, Tan SM, Ali-Shah ST, Guiry PJ, El-Osta A, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

J Am Soc Nephrol. 2018 May;29(5):1437-1448. doi: 10.1681/ASN.2017101112. Epub 2018 Feb 28.

23.

RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis.

Hagiwara S, Sourris K, Ziemann M, Tieqiao W, Mohan M, McClelland AD, Brennan E, Forbes J, Coughlan M, Harcourt B, Penfold S, Wang B, Higgins G, Pickering R, El-Osta A, Thomas MC, Cooper ME, Kantharidis P.

Diabetes. 2018 May;67(5):960-973. doi: 10.2337/db17-0538. Epub 2018 Feb 15.

24.

Heterogeneity of Reporting Outcomes in the Spine Surgery Literature.

Cooper ME, Torre-Healy LA, Alentado VJ, Cho S, Steinmetz MP, Benzel EC, Mroz TE.

Clin Spine Surg. 2018 May;31(4):E221-E229. doi: 10.1097/BSD.0000000000000578.

PMID:
29315117
25.

Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1).

Li J, Huynh P, Dai A, Wu T, Tu Y, Chow B, Kiriazis H, Du XJ, Bach LA, Wilkinson-Berka JL, Biros E, Walker P, Nataatmadja M, West M, Golledge J, Allen TJ, Cooper ME, Chai Z.

Diabetes. 2018 Apr;67(4):755-768. doi: 10.2337/db17-0134. Epub 2018 Jan 8.

26.

Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, Hamet P, Mancia G, Colagiuri S, Williams B, Grobbee DE, DeVries JH; ADVANCE Collaborative Group.

Diabetologia. 2018 Apr;61(4):780-789. doi: 10.1007/s00125-017-4539-1. Epub 2018 Jan 8.

27.

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.

d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME.

Diabetes Res Clin Pract. 2018 Feb;136:23-31. doi: 10.1016/j.diabres.2017.11.023. Epub 2017 Dec 2. Review.

PMID:
29196150
28.

Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2.

Moran CS, Biros E, Krishna SM, Wang Y, Tikellis C, Morton SK, Moxon JV, Cooper ME, Norman PE, Burrell LM, Thomas MC, Golledge J.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2195-2203. doi: 10.1161/ATVBAHA.117.310129. Epub 2017 Sep 21.

PMID:
28935757
29.

Diabetic kidney disease: as easy as aPC?

McFadyen JD, Cooper ME.

Blood. 2017 Sep 21;130(12):1390-1391. doi: 10.1182/blood-2017-08-798314. No abstract available.

30.

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS.

Kidney Int. 2018 Jan;93(1):231-244. doi: 10.1016/j.kint.2017.06.017. Epub 2017 Aug 30.

PMID:
28860019
31.

NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.

Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K.

Diabetes. 2017 Oct;66(10):2691-2703. doi: 10.2337/db16-1585. Epub 2017 Jul 26.

32.

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.

Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, Hamet P, Mancia G, Williams B, Welsh P, Sattar N, Shaw JE, Rahimi K, Chalmers J; ADVANCE Collaborative Group.

Diabetes Care. 2017 Sep;40(9):1203-1209. doi: 10.2337/dc17-0509. Epub 2017 Jul 6.

33.

Clinical Science: showcasing the breadth of the journal.

Cooper ME, Touyz RM.

Clin Sci (Lond). 2017 Jun 30;131(14):1559. doi: 10.1042/CS20171099. Print 2017 Jul 15.

PMID:
28667058
34.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.

35.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
36.

Dental Decay Phenotype in Nonsyndromic Orofacial Clefting.

Howe BJ, Cooper ME, Wehby GL, Resick JM, Nidey NL, Valencia-Ramirez LC, Lopez-Palacio AM, Rivera D, Vieira AR, Weinberg SM, Marazita ML, Moreno Uribe LM.

J Dent Res. 2017 Sep;96(10):1106-1114. doi: 10.1177/0022034517709961. Epub 2017 May 23.

37.

Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.

Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, Basu D, Heywood S, Kammoun HL, Flynn M, Whillas A, Hanssen NM, Febbraio MA, Westein E, Fisher EA, Chin-Dusting J, Cooper ME, Berger JS, Goldberg IJ, Nagareddy PR, Murphy AJ.

J Clin Invest. 2017 Jun 1;127(6):2133-2147. doi: 10.1172/JCI92450. Epub 2017 May 15.

38.

Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis.

Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KAM, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2017 Aug;66(8):2266-2277. doi: 10.2337/db16-1405. Epub 2017 May 9.

39.

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.

Gray SP, Jha JC, Kennedy K, van Bommel E, Chew P, Szyndralewiez C, Touyz RM, Schmidt HHHW, Cooper ME, Jandeleit-Dahm KAM.

Diabetologia. 2017 May;60(5):927-937. doi: 10.1007/s00125-017-4215-5. Epub 2017 Feb 3.

PMID:
28160092
40.

Hypoglycaemia in patients with diabetes mellitus and renal impairment.

Hettige TS, Cooper ME.

Diab Vasc Dis Res. 2017 Mar;14(2):166-168. doi: 10.1177/1479164116683082. Epub 2017 Jan 27. No abstract available.

PMID:
28128009
41.

Genetics of Diabetic Kidney Disease-From the Worst of Nightmares to the Light of Dawn?

Ma RC, Cooper ME.

J Am Soc Nephrol. 2017 Feb;28(2):389-393. doi: 10.1681/ASN.2016091028. Epub 2016 Nov 23. No abstract available.

42.

Set7 mediated interactions regulate transcriptional networks in embryonic stem cells.

Tuano NK, Okabe J, Ziemann M, Cooper ME, El-Osta A.

Nucleic Acids Res. 2016 Nov 2;44(19):9206-9217. Epub 2016 Jul 20.

43.

Protective Effect of Inflammasome Activation by Hydrogen Peroxide in a Mouse Model of Septic Shock.

Huet O, Pickering RJ, Tikellis C, Latouche C, Long F, Kingwell B, Dickinson B, Chang CJ, Masters S, Mackay F, Cooper ME, de Haan JB.

Crit Care Med. 2017 Feb;45(2):e184-e194. doi: 10.1097/CCM.0000000000002070.

44.

A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation.

Marshall JD, Heeke DS, Rao E, Maynard SK, Hornigold D, McCrae C, Fraser N, Tovchigrechko A, Yu L, Williams N, King S, Cooper ME, Hajjar AM, Woo JC.

PLoS One. 2016 Oct 13;11(10):e0164632. doi: 10.1371/journal.pone.0164632. eCollection 2016.

45.

Treatment of Distal Femur Nonunion Following Initial Fixation with a Lateral Locking Plate.

Ebraheim NA, Buchanan GS, Liu X, Cooper ME, Peters N, Hessey JA, Liu J.

Orthop Surg. 2016 Aug;8(3):323-30. doi: 10.1111/os.12257.

PMID:
27627715
46.

NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis.

Di Marco E, Gray SP, Kennedy K, Szyndralewiez C, Lyle AN, Lassègue B, Griendling KK, Cooper ME, Schmidt HHHW, Jandeleit-Dahm KAM.

Free Radic Biol Med. 2016 Aug;97:556-567. doi: 10.1016/j.freeradbiomed.2016.07.013. Epub 2016 Jul 19.

47.

Genetic Modifiers of Patent Ductus Arteriosus in Term Infants.

Patel PM, Momany AM, Schaa KL, Romitti PA, Druschel C, Cooper ME, Marazita ML, Murray JC, Dagle JM.

J Pediatr. 2016 Sep;176:57-61.e1. doi: 10.1016/j.jpeds.2016.05.066. Epub 2016 Jun 22.

48.

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.

Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M.

Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2. Epub 2016 Jun 17.

PMID:
27316632
49.

Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- mice.

Di Marco E, Gray SP, Chew P, Kennedy K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Clin Sci (Lond). 2016 Aug 1;130(15):1363-74. doi: 10.1042/CS20160249. Epub 2016 May 17.

PMID:
27190136
50.

The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Chow BS, Koulis C, Krishnaswamy P, Steckelings UM, Unger T, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Diabetologia. 2016 Aug;59(8):1778-90. doi: 10.1007/s00125-016-3977-5. Epub 2016 May 11.

PMID:
27168137

Supplemental Content

Loading ...
Support Center